FDA rejects PTC’s DMD drug Translarna

26th October 2017 Uncategorised 0

PTC Therapeutics will need to carry out at least one further trial to demonstrate the effectiveness of its Duchenne Muscular Dystrophy therapy Translarna if it is to have a chance of bagging its approval in the US.

More: FDA rejects PTC’s DMD drug Translarna
Source: News